DOES THE SCALE SAME-TT2R2 FUNCTIONS IN REAL CLINICAL PRACTICE?


Cite item

Full Text

Abstract

◆The possibilities of anticoagulant therapy in patients with atrial fibrillation significantly increased during last years. The warfarin therapy can be ineffective in those patients who can't neatly follow regimen of treatment, to control international normalized ratio in blood or international normalized ratio is retained with difficulty on recommended level. The scale SAMe-TT2R2 is considered as appropriate one to apply for more exact preliminary evaluation of possibility of achieving anticoagulation under application of antagonists of vitamin K. The purpose of study was to validate scale SAMe-TT2R2 on the group of observed out-patients in a real clinical practice. The study included 55 patients receiving warfarin because of non-valvular atrial fibrillation. In 30 patients (54.5%) a paroxysmal atrial fibrillation was observed and in 25 patients (45.5%) - permanent form of this disease. The examined group included 14 females and 41 males with average age of 71,3 ± 7,52 years. The patients receiving warfarin were in target range of international normalized ratio (2-3) 64,3 ± 12,91%of intake time. The percentage of patients residing within target range of international normalized ratio 60% of time and more comprised 58.9%. In average, patients taking during a year warfarin as anticoagulant controlled international normalized ratio 9,6 ± 0,41 times. In the examined group, 30 patients had according scale SAMe-TT2R2 0-1 point and 25 patients - 2 and more points. The scale had low diagnostic value (the square under ROC-curve 0.582), low sensitivity model 0.429 and moderate specificity 0.758 in relation to prediction of residence time in the target range of international normalized ratio 60%. For the value TTR 60% the diagnostic value turned out higher - 0.619 (sensitivity 0.547, specificity 0.789).

About the authors

Larisa O. Minushkina

The Central state medical Academy of the Administration of the President of the Russian Federation; The Polyclinic № 2 of the Administration of the President of the Russian Federation

Email: minushkina@mail.ru
doctor of medical sciences, professor of the chair of therapy, cardiology and functional diagnostic with the course of nephrology «The Central State Medical Academy» of the Administration of the President of the Russian Federation, 121359, Moscow 121359, Moscow, Russian Federation; 119146, Moscow, Russian Federation

A. G Azizova

The Polyclinic № 2 of the Administration of the President of the Russian Federation

119146, Moscow, Russian Federation

T. V Voskresenskaya

The Polyclinic № 2 of the Administration of the President of the Russian Federation

119146, Moscow, Russian Federation

References

  1. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37(38): 2893-962.
  2. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 1993; 69(3): 236-9.
  3. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y.H. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013; 144(5): 1555-63.
  4. Zulkifly H., Lip G.Y.H., Lane D.A. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients treated with vitamin K antagonists: A review. Heart Rhythm. 2017; Pii: S1547-5271(17)31366-8.
  5. Liu J., Wang N., Qin L., Liu J., Xi S., Wang X., et al. Integrating genotypes in the SAMe-TT2R2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. Int. J. Cardiol. 2017; 241: 358-63.
  6. Bryk A.H., Plens K., Undas A. Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation. Cardiol. J. 2017; 24(5): 477-83.
  7. Lip G.Y., Waldo A.L., Ip J., Martin D.T., Bersohn M.M., Choucair W.K., et al. Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT). Am. J. Cardiol. 2016; 118(11): 1680-4.
  8. Guo Y., Chen Y., Lane D.A., Liu L., Wang Y., Lip G.Y.H. Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. Am. J. Med. 2017; 130(12): 1388-96.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies